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Synthesis of orthogonally protected thioamide-containing dipeptides for use in solid-
phase peptide synthesis 
 
Kim Manzor and Fintan Kelleher*  
 
Molecular Design & Synthesis Group, Centre of Applied Science for Health, Institute of 
Technology Tallaght, Dublin 24, Ireland 
 
Abstract 
Orthogonally protected thioamide-containing dipeptides were efficiently and cleanly 
prepared from the precursor dipeptides using Curphey’s method (P4S10, 
hexamethyldisiloxane (HMDO), reflux, DCM) in 67-96% isolated yield. This was in contrast 
to the use of Lawesson’s or Berzelius’ reagents where significant issues with reaction non-
completion, decomposition and purification were observed. Subsequent clean removal of the 
dipeptides’ t-butyl ester protecting groups gave thioamide dipeptide acids which were suitable 
for use in solid-phase peptide synthesis (SPPS). 
 
Keywords: thioamide; thionation; Curphey’s method; thiopeptides. 
 
The WHO has recognised antimicrobial resistance (AMR) as one of the greatest challenges 
facing humankind, with some bacterial species already becoming resistant to all currently 
used antibiotics.1 A recent report has predicted that, if the situation is left unchecked, by 
2050 up to 10 million people annually will die from bacterial infections, with an overall 
cost of US$100 trillion.2 However, the pipeline of new antibiotics for tackling this crisis is 
very low since most of the world’s major pharmaceutical companies no longer have 
antibiotic discovery programmes. In order to address this critical issue, there is an urgent 
global need for the development of a wide range of new antibiotic classes. The worldwide 
market for peptide-based therapeutics is forecasted to grow to $23.7 billion by 2020,3 
where chemically synthesised peptides will be a significant, and growing, proportion of 
this figure. Peptide-based antimicrobials are a class that has significant potential in 
combatting AMR, and include lantibiotics and antimicrobial peptide (AMPs).4 A further 
class is the thiopeptide antibiotics, which include thiostrepton, siomycins and thiopeptins, 
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amongst many others.5 The chemical synthesis of many thiopeptides requires the efficient 
preparation of thioamides, in place of amides, as the peptide link. These thioamides can 
then be left with the thioamide peptide bond intact as bioisosteres, or further converted to 
the thiazoline and thiazole heterocyclic moieties, which are common in thiopeptide 
antibiotics. Peptides containing thioamides are known in some cases to improve aqueous 
solubility and pharmacokinetic properties, such as half-life.6 The synthesis of thioamides 
has been reviewed, and one of the principal methods used is the thionation of amides.7 A 
large number of methods have been developed for the thionation of carbonyl groups to 
their thiocarbonyl analogues, where the main reagents include Lawesson’s reagent,8 
Berzelius’ reagent9, more recently Curphey’s method.10 The use of a P4S10-pyridine 
complex was also reported by Bergman and co-workers in 2011.11 
 
As part of a project for preparing antimicrobial peptides containing specific thioamide 
isosteres in place of amides by solid-phase peptide synthesis (SPPS), there was a need for 
the efficient synthesis of specific peptidic thioamide moieties. It is known that it is not 
possible to conduct the thionation reaction of an amide bond when the peptide is already 
on a solid-phase resin. It is also not possible to selectively thionate a particular amide in an 
oligopeptide or polypeptide sequence. Therefore, we required the solution-phase synthesis 
of orthogonally protected dipeptide fragments containing the thioamide peptide bond, 
where the fragment could then be incorporated into a peptide sequence using SPPS. Our 
initial targets required the preparation of dipeptides of type A) Fmoc-NH-Ile-Xaa-COOBut, 
where Xaa was glycine, alanine, phenylalanine, and type B) Fmoc-NH-Xaa-Leu-COOBut 
where Xaa were similar residues to type A (Fig. 1). Fmoc SPPS was selected as the method 
of choice for preparation of the required peptides. 
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Figure 1. Structures of the two types of dipeptide precursor targets 
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A review of the literature showed that Strømgaard and co-workers12 recently reported the 
successful use of Lawesson’s reagent in tetrahydrofuran at room temperature for the 
preparation of thioamide-containing dipeptides in good isolated yields of >80%. Before 
attempting the amide thionation reaction, the dipeptide precursors for the type A fragments 
were efficiently prepared in acetonitrile, in 93-97% isolated yield, by the coupling of 
Fmoc-L-Ile-COOH with the required amino acid protected as its t-butyl ester, using HBTU 
in the presence of triethylamine (Scheme 1).12 
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R = PhCH2- (1)  97%
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Scheme 1. Synthesis of Type A dipeptides and their thioamide analogues. Reagents and 
conditions; i) Et3N, HBTU, CH3CN, rt, 2h; ii) P4S10, (Me3Si)2O, DCM, reflux 
 
The type B dipeptides were similarly prepared by the coupling of Fmoc protected L-amino 
acids with L-leucine t-butyl ester under similar reaction conditions. In this case the isolated 
yields were slightly lower (86-96%).  
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Scheme 2. Synthesis of Type B dipeptides and their thioamide analogues. Reagents and 
conditions; i) Et3N, HBTU, CH3CN, rt, 2h; ii) P4S10, (Me3Si)2O, DCM, reflux 
 
With the dipeptides in hand, the next step involved selective thionation of the amide group 
to a thioamide in the presence of both carbamate and ester functional groups. Although 
Bergman and co-workers reported the use of the P4S10-pyridine complex for amide 
thionation, the reaction conditions required reflux in acetonitrile (b.pt. 85 oC), pyridine 
(b.pt. 115 oC) or in dimethyl sulfolane at 165-175 oC. In our experience, heating of 
orthogonally protected dipeptides at temperatures of 80-90 oC, leads to significant 
decomposition, so it was felt that Bergman’s method was too harsh for the examined 
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dipeptide substrates. Likewise Shibihara and Murai’s method for converting amides to 
thioamides using elemental sulfur required reflux in toluene at 115 oC,13 while Poupaert 
and co-workers reported the use of P4S10 in the presence of Al2O3 in 1,4-dioxane at reflux 
(b.pt. 101 oC).14 Both sets of conditions were also considered too harsh in our case. 
 
As a result, Strømgaard’s method for selective amide thionation in the presence of both 
carbamate and ester carbonyl groups was used.12 However, in our hands it was found that 
even after further multiple additions of molar equivalents of Lawesson’s reagent, 
incomplete reaction was observed with significant quantities of the starting dipeptide still 
present in each case. It was also found when using this method, that purification of the 
required thioamide peptide was laborious due to difficulties in separating the required 
compounds from by-products formed from the Lawesson’s reagent. Significant time and 
effort was expended trying to optimise this reaction by changing the solvent, temperature, 
reaction time, and the use of new batches of Lawesson’s reagent, however, to no avail. A 
significant amount of the starting dipeptide was present, in each case, as well 
decomposition products were observed. 
 
Moving on, Berzelius’ reagent (P4S10) was used, but as for Lawesson’s reagent after many 
attempts, using a variety of reaction conditions, incomplete reaction and/or decomposition 
was always observed. As for the use of Lawesson’s reagent, significant difficulties with 
purification also arose.  
 
Finally Curphey’s method,10 using P4S10 (1.1 molar equiv.) in the presence of 
hexamethyldisiloxane (HMDO, 5.5 molar equiv.) was attempted. After some optimisation it 
was found that the use of dichloromethane as solvent at reflux, as well as the further addition 
of the same amount of P4S10 and HMDO after 5 h, and close monitoring of the reaction by 
TLC, consistently gave the desired thioamide products in 67-96% isolated yields, after 
purification by column chromatography (Schemes 1 and 2). No evidence of any remaining 
starting dipeptides was observed by TLC and the chromatographic purification was 
straightforward. 
 
The dipeptides and their thioamide analogues were fully characterised using a range of 
spectroscopic techniques, where 1H and 13C NMR spectroscopy showed the diagnostic 
downfield movement in the chemical shifts for both the carbon atom of the amide carbonyl 
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group and the amide N-H proton, when the amides were converted to their thioamide 
derivatives12 (Table 1). 
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Table 1. Key 1H and 13C NMR chemical shifts for the characterisation of dipeptides and 
thioamide derivatives 
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With the orthogonally protected thioamide dipeptides in hand it was then required that the t-
butyl ester be efficiently removed, so that the Fmoc-protected thioamide dipeptides with a free 
carboxylic acid could be used for SPPS. This was readily achieved (~90% yield) by treating 
the orthogonally protected thioamide dipeptides with 50% TFA in DCM in the presence of 
triphenylsilane as a scavenger (Scheme 3). 
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Scheme 3. Representative examples of deprotection of t-butyl ester group to give 
thioamide dipeptides 13 and 14, ready for SPPS. Reagents and conditions; i) 50% TFA in 
DCM, Ph3SiH, rt, 2h 
 
In conclusion the use of P4S10 and HMDO to cleanly and selectively thionate the peptide 
bond of orthogonally protected dipeptides was achieved to consistently give the desired 
compounds in good yields. This was in contrast to the use of Lawesson’s reagent or 
Berzelius’ reagent, where incomplete reaction and/or decomposition, as well as difficulties 
with purification, was observed in every case. Subsequent C-terminus deprotection gave 
the thioamide dipeptide fragments (13 and 14) suitable for incorporation into peptide 
sequences by SPPS. The thioamide dipeptides are now being used for this purpose and the 
results of these studies will be reported in due course. 
 
Supplementary data 
Synthetic methods and characterisation data for compounds 1-14. 
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